Publication

Article

CURE

Summer 2014
Volume13
Issue 2

Group Launches Global Initiative to Support Cancer Research

Project: EveryChild is collecting biologic samples, such as blood, tissue and other specimens, from children undergoing treatment.

The world's largest organization dedicated to childhood and adolescent cancer research is engaging more than 200 pediatric cancer programs around the U.S. to participate in collecting biologic samples, such as blood, tissue and other specimens, from children undergoing treatment. Called Project:EveryChild, the purpose of the Children’s Oncology Group (COG) initiative is to develop new treatments for childhood cancers that are both common and rare, including leukemias, lymphomas, solid tumors and tumors of the central nervous system. The information gleaned from these biospecimens will be entered in a secure database that can be accessed by researchers worldwide with the hope they can utilize it to discover more effective and less toxic treatment options, as well as cures.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.